Buprenorphine (SL/depot)

Partial Opioid Agonist·Addiction Medicine

Maintenance treatment for Opioid Use Disorder

S8PBSOUD / S8Subutex (SL), Buvidal (SC), Sublocade (SC)Sublingual buprenorphine pro…+1

Max Dose

Buvidal 160 mg/month; Sublocade 300 mg/month

Half-life

Days to Weeks

Resp. Depression

CEILING

Precip. W/D

CRITICAL RISK

Rapid Summary

Overview

Buprenorphine partial mu-opioid agonist for opioid-dependence treatment, available as sublingual products and long-acting SC depot injections. Depot products reduce daily dosing burden but require correct induction and follow-up.

Maximum Dose

Depot maximums differ by product: Buvidal monthly dosing can be 64-160 mg; Sublocade monthly dosing is usually 300 mg for two months then 100 mg, with 300 mg monthly maintenance in selected tolerated inadequate-response cases.

Clinical Focus

Depot buprenorphine should follow appropriate buprenorphine induction/tolerance confirmation. Giving buprenorphine too soon after full agonists can precipitate withdrawal; depot administration makes rapid dose reversal difficult.

Bottom Line

Buprenorphine (SL/depot) is a partial opioid agonist for opioid dependence and pain, but initiation requires mild withdrawal state and the ceiling effect limits analgesic utility in severe acute pain.

Formulation & Access

Brand Names

Subutex (SL), Buvidal (SC), Sublocade (SC)

Oral Routes

Sublingual tablets (0.4, 2, 8 mg). Must dissolve completely.

Parenteral

Long-acting SC depot injection only; administer by a healthcare professional. Sublocade is injected into abdominal subcutaneous tissue and must not be injected IV, IM, or intradermally.

Prescribing & PBS

S8. PBS search shows buprenorphine modified-release injection strengths under S100 HSD Community Access; confirm product-specific item/restriction and jurisdictional OAT requirements before prescribing.

Indications & Use

Primary

PBSTGA

Maintenance treatment for Opioid Use Disorder.

Clinical Place

The gold standard. The monthly SC depots have revolutionized OUD by removing the need for daily pharmacy visits, completely halting diversion/street sale.

Quick reference

Class & Role

Partial Opioid Agonist — Partial mu-opioid agonist with extreme receptor affinity.

Route / Formulation

Sublingual buprenorphine products for induction/transition; depot products are healthcare-professional SC injections: Buvidal weekly/monthly and Sublocade monthly abdominal injection.

Usual Dose & Max

SL induction/transition is individualised. Buvidal: weekly 8-32 mg or monthly 64-160 mg. Sublocade: usually 300 mg monthly for 2 months, then 100 mg monthly; 300 mg monthly may continue if tolerated and response is inadequate.

Key Indication Doses

Opioid Use Disorder (Sublingual Induction): SL 2-4 mg STAT only when the patient is in OBJECTIVE moderate withdrawal (COWS > 12). Titrate to 16-24 mg/day. Subcutaneous Depot (Buvidal): SC Weekly (16-32 mg) or Monthly (64-128 mg). Does not require cold chain. Subcutaneous Depot (Sublocade): SC Monthly (100-300 mg) deep abdominal injection. Requires cold chain.

Best Uses

Avoid / Cautions

Avoid depot initiation without established buprenorphine tolerance/appropriate induction. Use caution with respiratory insufficiency, hepatic impairment, pregnancy/lactation, CNS depressants, and high-risk injection-site or diversion concerns.

Key Risks

Neurological: Precipitated withdrawal (if given too early). HIGH — Headache, insomnia, sweating. Gastrointestinal: Constipation, nausea. Tissue: Sublocade forms a solid lump under the skin that can be painful. Must be injected into abdominal fat.

Key Interactions

Full Opioid Agonists (Morphine/Oxycodone). Because buprenorphine's grip on the receptor is so tight, standard opioids will bounce off. If the patient breaks their leg, standard analgesia will fail. They require Ketamine, nerve blocks, or massive ICU-level Fentanyl doses to break through the blockade.

Monitoring

Before depot: confirm buprenorphine tolerance/withdrawal stability, baseline LFTs, viral hepatitis status where relevant, sedation/respiratory status, injection-site reactions, pregnancy/lactation status, and CNS depressant use.

Clinical Pearl

A toddler taking a sip of Methadone will die. A toddler eating a Buprenorphine tablet will likely just sleep heavily. The 'ceiling effect' means that no matter how much Buprenorphine is taken, the respiratory depression maxes out and stops before it becomes fatal.

Access

Subutex (SL), Buvidal (SC), Sublocade (SC)8 mg tablet

Brand: Subutex (SL), Buvidal (SC), Sublocade (SC)
Formulation: Sublingual tablets (0